



Attorney Docket No.: 6258.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Madsen et al

Serial No.: 09/996,023

Group Art Unit: 1626

Filed: November 16, 2001

Examiner: Stockton, Laura Lynne

For: Glucagon Antagonists/Inverse Agonists

Confirmation No. 2060

PATENT

MAR 21 2003

TECH CENTER 1600/2900

RECEIVED

AMENDMENT AND RESPONSE

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

This Amendment is submitted in response to the Office Action mailed October 11, 2002 in which the Examiner rejected claims 1, 2, 4, 5, 35 and 36 and withdrew claims 19-34 from consideration. Reconsideration is respectfully requested in view of the following amendments and remarks.

IN THE CLAIMS:

Please cancel claims 19-34 without prejudice.

Please amend the claims as follows:

1. (Amended) A compound which is selected from

3-{4-[1-(4-cyclohexylphenyl)-3-(3-trifluoromethoxyphenyl)ureidomethyl]benzoylamino}-propionic acid,

3-{4-[1-(4-cyclohex-1-enylphenyl)-3-(3-trifluoromethoxyphenyl)ureidomethyl]benzoylamino}-propionic acid,

3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3-trifluoromethoxyphenyl)ureidomethyl]benzoylamino}-propionic acid,

3-{4-[1-(4-cyclohexylcyclohexyl)-3-(3-trifluoromethylphenyl)ureidomethyl]benzoylamino}-propionic acid,

3-{4-[1-(4-cyclohexylphenyl)-3-(3-trifluoromethylphenyl)ureidomethyl]benzoylamino}propionic acid,

3-{4-[1-(4-cyclohexylphenyl)-3-(3-bromophenyl)ureidomethyl]benzoylamino}propionic acid,